BridgeBio Pharma, Inc. — Director's Dealing 2023

Mar 1, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-02-21

Reporting Person: MCCORMICK FRANK (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1200065	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$17.00	2029-06-26	Common Stock (265463)		Direct
Stock Option (right to buy)	$1.05	2029-09-17	Common Stock (10549)		Direct
Stock Option (right to buy)	$40.03	2031-12-01	Common Stock (18566)		Direct

Footnotes

F1: 237,810 shares have vested to date. The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such date.